| Health / Medical Topics |
PF-02341066
A drug used to treat advanced non-small cell lung cancer that has a mutated (changed) form of a gene called anaplastic lymphoma kinase (ALK). It is also being studied in the treatment of other types of cancer. PF-02341066 blocks the protein made by the mutated ALK gene. Blocking this protein may stop the growth and spread of cancer cells. PF-02341066 may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called crizotinib, MET tyrosine kinase inhibitor PF-02341066, and Xalkori. (NCI Dictionary)
YOU MAY ALSO LIKE
A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called protein tyrosine kinase…
A regimen consisting of cisplatin and continuous infusion fluorouracil used as either induction (neoadjuvant) therapy or concurrently with radiation (chemoradiation), for the…
Lymphoid cell tissue in the small intestinal mucosa.
A thymidine kinase-deleted vaccinia virus expressing human GM-CSF (hGM-CSF) with oncolytic activity. Upon intratumoral or intravenous administration, pexastimogene-devacirepvec may selectively infect and…
A genetic disorder in which polyps form in the intestine and dark spots appear on the mouth and fingers. Having Peutz-Jeghers syndrome…
A non-neoplastic polyp that arises from the stomach and is characterized by the presence of smooth muscle branching bands, and hyperplasia with…
